Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide rollover continuation study in prostate cancer
NL-OMON52006Phase 3Recruiting
- Sponsor
- Bayer
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of treatment-emergent serious adverse events and 1 more. Started Feb 2022; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52006.